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In the present study, we report the comparative proteome profiles of proteins solubilized from 37 breast
cancer surgical tissues, normalized for the actin content. Blood-derived proteins were excluded from
the analysis. Among the tumor-derived protein spots, a large proportion (39%) was found present in
all patients. These included several glycolytic enzymes, detox and heat shock proteins, members of
annexin and S100 protein families, cathepsin D, and two “rare” proteins, DDAH2 involved in the
angiogenesis control, and the oncogene PARK7. Other proteins, such as psoriasin, galectin1, cofilin,
peroredoxins, SH3L1, and others, showed sporadic presence and high expression level, which suggests
their possible role for patient stratification.
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Introduction
The exponentially increasing volume of information ex-
tracted from genomic and proteomic applications on cancer,
while providing new insights into molecular composition of
cancer cells and tissues, imposes new challenges on data
rationalization as a tool for clinically relevant biomarker
discovery. In recent years, the major agencies for cancer
research have committed extensive resources to identify and
make available in clinical practice biomarkers that can help to
demonstrate the presence of a tumor and its malignant
potential or to predict tumor behavior, prognosis, or response
to treatments.1 The increasing number of detected proteins in
the different laboratories conducting proteomic research has
generated many candidate biomarkers with potential clinical
value. However, translation from bench to bedside of the
patient has proven to be more difficult than previously
expected. A major reason is the complexity of the cancer as a
biological system under its different hierarchical levels: genes,
proteins, cells, and tissues.
Breast cancer represents the most frequent and potentially
aggressive type of cancer and the leading cause of cancer deaths
in women in the Western countries. Moreover, breast cancer
is one of the most enigmatic and poorly predictable cancers
in its evolution, likely because it includes several different forms
that behave differently among patients. This biological hetero-
geneity is consistent with observed varied responses to thera-
pies across patient populations.
Current clinical parameters for breast cancer diagnosis and
cure are tumor size, axillary lymph node status, histological
grading, and presence or absence of metastases.2 Prognostic/
predictive properties, such as estrogen and progesterone recep-
tor status, and human epidermal growth factor receptor (HER-
2/neu) status, are currently used for therapeutic decision.3,4
Conversely, it is now emerging that the number of genetic
mutations5 and epigenetic deregulations6 in cancer is far more
higher than previously thought.
Therefore, proteomic screening for differential protein ex-
pression in subsets of tumor samples is an essential tool to
generate databases, to contribute to the knowledge of biological
pathways in a given cancer tissue, and to allow a molecular
classification of cancer for patient stratification and biomarker
discovery.
Eligibility of clinically relevant biomarkers for therapeutic use
implies at least two conditions: easy accessibility from the
bloodstream or tissues, and elevated expression levels with
respect to the normal tissues.
In our laboratories, we have recently developed adequate
extraction procedures for proteomic profiling of breast cancer
tissues derived from surgery.7 A limitation of this kind of
approach is the mentioned heterogeneity of breast cancer
tissues, for which proteomic profiling may be influenced by
extension and amount of neoplastic cells within the host
stroma. To minimize this limitation and to introduce a objective
criterion to compare proteomes of different tissues, the expres-
sion levels of individual proteins were normalized for actin
content in each tissue extract.
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In the present study, we analyzed the proteomic profiles of
surgical tissues of 37 patients diagnosed for ductal infiltrating
breast cancer.
Collectively, we produced a catalogue of 160 proteins. This
number includes different isoforms of the same protein, as well
as proteins derived from blood. The latter were filtered away
before generating protein clusters according to an arbitrary
scale of expression levels calculated as relative aboundance
(%Vol) of each protein spot normalized for actin content. By
this criterion, we produced six protein clusters, namely, very
highly expressed, highly expressed, medium/highly expressed,
medium/lowly expressed, lowly expressed, and very lowly
expressed proteins.
Interestingly, a large proportion of the tumor-derived pro-
teins (39%) was found present in all patients. These included
several glycolytic enzymes, detox and heat shock proteins,
members of annexin and S100 protein families, cathepsin D,
and two proteins not described before in breast cancer tissue
proteomics, namely, DDAH2, involved in the angiogenesis
control, and the oncogene PARK7. Other proteins, including
psoriasin, galectin1, cofilin, peroredoxins, and SH3L1, showed
sporadic presence and high expression level, which suggests
their possible role for patient stratification.
We believe that this information may substantially contribute
to the progress of protein profiling of breast cancer and help
to organize subclasses for clinical applications. The statistical
correlations with clinical parameters were not included in this
study, because a larger population of patients is needed to
generalize the results. Therefore, a contribution of efforts in
this direction from several laboratories is to be encouraged.
Materials and Methods
Clinical Specimens. Sample management was performed
according to the bioethical recommendations. Aliquots of
breast cancer and its adjacent nontumoral tissues were ob-
tained during surgical intervention and immediately frozen in
Figure 1. Representative proteomic maps of one breast cancer
surgical tissue (A) and its matched nontumoral adjacent tissue
(B), derived from a random select patient. 2-DE separation was
performed on IPG gel strips (18 cm, 3.5–10 NL) followed by the
SDS-Page on a vertical linear-gradient slab gel (9–16%T). Protein
spots of known identity are labeled with the access number of
the Swiss-Prot/TrEMBL database. When present, different iso-
forms of the same protein are jointly labeled.
Figure 2. Proteomic maps of serum sample from a healthy
subject (A) and a protein extract from a breast fibroadenoma (B),
showing the pattern of prominent serum proteins.
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liquid nitrogen and stored at -80 °C until use. The patients
did not receive any cytotoxic/endocrine treatment prior to
surgery. In each cases, nontumoral tissue was located at least
5 cm away from the primary tumor. Diagnosis of ductal breast
cancer (G2/G3) was confirmed histopathologically.
Sample Preparations. The frozen breast tissue samples were
washed several times with phosphate-buffered saline and
homogenized in RIPA buffer (50 mM Tris, pH 7.5, 0.1% Nonidet
P-40, 0.1% deoxycholate, 150 mM NaCl, and 4 mM EDTA) and
a mixture of protease inhibitors (0.01% aprotinin, 10 mM
sodium pyrophosphate, 2 mM sodium orthovanadate, and 1
mM PMSF). The extraction was carried out overnight at 4 °C
with the same buffer. The total cellular lysate was centrifuged
at 15 000 rpm for 20 min to clear debris, and the supernatant
was dialysed against ultrapure distilled water, lyophilised, and
stored at -80 °C until analysis. Protein concentration in the
cellular extracts was determined using the Bradford method.8
Two-Dimensional Gel Electrophoresis. The proteins ex-
tracted from breast cancer tissue and normal adjacent tissue
were solubilized in a buffer containing 4% CHAPS, 40 mM Tris,
and 65 mM DTE in 8 M urea. Aliquots of 45 µg (analytical gels)
or 1.5 mg (preparative gels) of total proteins were separately
mixed with 350 µL of rehydration solution containing 8 M urea,
2% CHAPS, 10 mM DTE, and 0.5% carrier anpholytes (Resolyte
3.5–10) and applied for IEF using commercial sigmoidal IPG
strips, 18 cm long with pH range 3.5–10. The second dimension
was carried out on 9–16% linear gradient polyacrylamide gels
(SDS-PAGE), and the separated proteins were visualized by
ammoniacal silver staining. Two or three replicas were per-
formed for each patient.
Image Acquisition and Data Analysis. Silver-stained gels
were digitized using a computing densitometer and analyzed
with ImageMaster 2D Platinum software (Amersham Bio-
sciences, Sweden). Gel calibration was carried out using an
internal standard and the support of the ExPaSy molecular
biology server, as described.9 Quantitative variations in protein
expression levels were calculated as the volume of the spots
(i.e., integration of optical density over the spot area). To correct
for differences in gel staining, spot volumes relative to the sum
of the volume of all spots on each gel (%Vol) were calculated
by the software. Furthermore, for comparative profiling, indi-
vidual spot %Vol was normalized for the actin %Vol value. The
resulting figure was considered an indicator of protein expres-
sion level and utilized for protein clusterization.
N-terminal Protein Sequencing. N-terminal microsequenc-
ing was performed by automated Edman degradation in a
Protein Sequencer (Procise 491, Applied Biosystems) on protein
samples electrotransferred onto PVDF membranes at 50 V for
30 min at 4 °C.10 The Swiss-Prot/TrEMBL/BLAST databases were
used for online sequence similarity search at http://www.
expasy.ch/tools/#similarity.
Matrix-Assisted Laser Desorption Ionization-Time of
Flight (MALDI-TOF). Mass spectrometric sequencing was
carried out after in-gel digestion of protein spots, using
sequencing-grade trypsin (20 µg/vial), according to the method
of Shevchenko et al. 11 with some modification.10 The tryptic
peptide extracts were dried in a vacuum centrifuge and
redissolved in 10 µL of 0.1% trifluoroacetic acid (TFA). The
matrix, R-cyano-4-hydroxycinnamic acid (HCCA), was pur-
chased from Sigma-Aldrich. A saturated solution of HCCA (1
µL) at 2 mg/200 µL in CH3CN/H2O (50:50 (v/v)) containing 0.1%
TFA was mixed with 1 µL of peptide solution on the MALDI
plate and left to dry. MALDI-TOF mass spectra were recorded
on a Voyager DE-PRO (Applied-Biosystems) mass spectrometer,
in the 500–5000 Da mass range, using a minimum of 100 shots
of laser per spectrum. Delayed extraction source and reflector
Figure 3. Panel showing an experimental window from ImageMaster 2D Platinum software containing the sections of actin spots (white
crosses) from the matched two-dimensional gels of the 37 breast cancer surgical tissues, indicated from P01 to P37.
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equipment allowed sufficient resolution to consider MH+ of
monoisotopic peptide masses. Internal calibration was done
using trypsin autolysis fragments at m/z 842.5100, 1045.5642,
and 2211.1046 Da. Peptide mass fingerprinting was compared
to the theoretical masses from the Swiss-Prot or NCBI sequence
databases using Mascot (http://www.matrixscience.com/). Typi-
cal search parameters were as follows: (50 ppm of mass
tolerance, carbamidomethylation of cysteine residues, one
missed enzymatic cleavage for trypsin, a minimum of four
peptide mass hits was required for a match, methionine
residues could be considered in oxidized form, no restriction
was placed on the isoelectric point of the protein, and a protein
mass range from 5 to 100 kDa was allowed.
Western Blotting. For immune detection, the gels (9–16%
linear gradient SDS-PAGE) were electrotransferred onto nitro-
cellulose membrane (HyBond ECL, Amersham) at 50 V for 1 h
at 4 °C. After electrotransfer, the membranes were blocked with
5% of dry milk in T-TBS for 1 h and probed with one of the
following antibodies (Santa Cruz): monoclonal anti-PARK7,
anti-S10A7, anti-GDIR, and goat polyclonal anti-DDAH1 and
anti-DDAH2, at 1:1000 diluted with 1%milk in T-TBS. Following
incubation with anti-mouse or anti-goat peroxidase-linked
antibody (Amersham), the reaction was revealed using en-
hanced chemioluminiscence (Pierce), according the manufac-
turer’s instructions.
Figure 4. Diagram illustrating the distribution of the identified proteins among the 37 patients, designated from P01 to P37. Alphabetical
letters following protein abbreviated names indicate the different isoforms, starting from the more acidic one. The black boxes indicate
absence of proteins in the map of the corresponding patient, and the crosses in each box indicate the patient expressing the given
protein at its highest level.
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Results and Discussion
The methodology described to isolate proteins from the
surgical specimens allows the releasing of salt-soluble proteins
from cellular and extracellular compartments. No efforts were
made to extract ECM components, because they not pertinent
to the present research.
We have recently reported the comparative proteomic
profiles of 13 pairs of surgical samples obtained from patients
with ductal infiltrating breast cancer.7 As expected, the con-
tribution of cellular proteins to the proteomic complexity, was
much higher in the tumor extracts than in their paired
nontumoral conterparts. As an example, panels A and B of
Figure 1 show two proteomic maps, respectively, generated
from a breast cancer tissue extract and its paired nonaffected
tissue. The labels on the map indicate the access number
(Swiss-Prot/TrEMBL database) of the identified proteins. A
remarkable difference between the two proteomic maps for
protein spot composition is clearly observed. We suggest that
this different pattern is due to the reduced amount of parenchima
in the mammary gland of healthy adult women, opposed to
the abundant cell population present in the tumor core. Indeed,
the proteomic profile of nontumoral tissue extracts reveals the
almost exclusive presence of serum and blood proteins,
consisting mainly of albumin, immunoglubulins, and other
globulins. Figure 2A shows the serum proteome of a healthy
subject compared with the normal tissue extract. Similarly, the
fibroadenoma proteome, a benign breast lesion, dispalys a very
small amount of cellular proteins with respect to blood-derived
proteins (Figure 2B).
The collection of proteins so far identified in our tumor
samples contains 160 proteins, including isoelectric variants
and bood-derived proteins (supplemental Table 1 in Supporting
Information). When present, the different isoforms of the same
protein are indicated by alphabetical letters, starting from the
more acidic one.
Since the cellularity of the tumor biopsy, that is, cell densities
within an area of the surgical sample, may be very variable
among the different subjects, measurements of relative expres-
sion levels (%Vol) of individual protein spots were normalized
in each map for actin content.
Figure 3 shows an experimental window containing the
sections of actin spots from the 37 two-dimensional gels,
testifying the variability of actin amount among the proteomic
maps of our study, likely as an effect of different degree of
cellularity in the samples examined, under the same quantity
of protein loading in the 2D-IPG.
Protein Presence-Absence. As shown in Figure 1A, the
tumor samples, besides the proteins of cellular origin, contain
variable amount of blood-derived proteins. The latter were
filtered out from our catalogue. The remaining amount, likely
representing tumor-related proteins, accounted for 87, 34 of
which, that is 39%, were expressed in all samples. Figure 4 is a
diagram illustrating the distribution of the identified proteins
among the 37 patients, indicated from P01 to P37. The black
boxes indicate absence of proteins in the map of the corre-
sponding patient, and the crosses in each box indicate the
patient expressing the given protein at its highest level among
the 37 chosen ones.
Figure 5. Protein clusters were generated by sorting proteins with the highest expression level among the 37 patients. The protein
spot expression level was calculated as the %Vol normalized for actin content, of each patient map, after subtraction of blood-derived
proteins. The range of values are expressed on an arbitrary scale, from 0.05 to >1, and indicated as: VHEP, very highly expressed
proteins (range 0.8-1); HEP, highly expressed proteins (0.6–0.79); M/HEP, medium/highly expressed proteins (0.4–0.59); M/LEP, medium/
lowly expressed (0.2–0.39); LEP, lowly expressed (0.1–0.19); VLEP, very lowly expressed (0.05–0.09).
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Interestingly, and in agreement with current knowledge,9,12
a major portion of ubiquitous proteins belong to the glycolytic
metabolism (12/34, i.e., 35%, including isoforms); seven protein
forms include 2 protein foldings (PDA1, and 3 isoforms of PPIA),
a calcium-binding chaperone (CALR) and 2 heat shock proteins
(HSP74 and GRP94); four proteins are represented by 3
members of redox-defense machinery (SOD, THIO, GSTP1),
and one recently identified oncogene PARK7, a master regulator
of antioxidant transcriptional responses.13 Other intersting
components of this proteomic profiling are 2 regulators of the
transduction machinery (GDIR and GDIS), the Dimethylargini-
nase 2 (DDAH2), a relevant enzyme involved in the angiogen-
esis control,14 and a subgroup of proteins like ANXA2, S10A6
calcium-binding protein, and vinculin which individually and/
or in synergy are important players of events related to invasion
and metastasis.15–19
Finally, another ubiquitously expressed protein was the
cathepsin D, a controversial prognostic marker for breast
cancer progression.20 This was detected under two isoelectric
variants with pI of 5.29 and 5.69, respectively, the latter being
usually the more aboundant.
It is worth to mention that several ubiquitous proteins are
multifunctional, therefore, may be involved in more metabolic
pathways, besides their major role in the cell. Indeed, HSP70
protein family, GRP94, and CALR may also exert a role in the
tumor immune-responses.21 Similarly, G3P, ENOA, PGAM1,
and TPIS, besides their role in the glycolytic pathway, are
known to exploit several diversified functions; that is, G3P2, is
known to facilitate membrane fusion, microtubule bundling,
and it is capable of nucleic acid binding;22,23 alpha-enolase
functions as a plasminogen receptor on some cell types,24 while
PGAM1 has been shown to substain indefinite proliferation in
embryonic fibroblasts.25 It has been also reported that triose-
phosphate isomerase activity, which play a key role in the
interconnection between the pentose phosphate pathway and
the lipid metabolism, tends to be higher expressed in immature
myeloid cells.26,27 Recently, it has also been demonstrated that
calreticulin has a role in regulating p53 function by affecting
its rate of degradation and nuclear localization.28
Protein Clustering According to the Expression Level. After
subtraction of proteins derived from blood, and normalization
for actin contents, we sorted the proteins by the highest
expression level among the 37 analyzed patients. These proteins
were then grouped according to an arbitrary scale, with values
(%Vol normalized for actin) ranging from 0.05 to >1. By this
criterion, we generated six protein clusters (Figure 5): (1) very
highly expressed proteins (VHEP, 14.94%), (2) highly expressed
proteins (HEP, 16.09%), (3) medium/highly expressed proteins
(M/HEP, 18.39%), (4) medium/lowly expressed (M/LEP, 39.08%),
(5) lowly expressed (LEP, 6.89%), and (6) very lowly expressed
(VLEP, 4.59%).
Remarkably, among the VHEP and HEP clusters are some
glycolytic enzymes, proteins of cellular defenses, proteins
belonging to the S100 family, and the 2 isoforms of CATD.
These two groups also include proteins with a very peculiar
property: their appearance is sporadic, but when present, their
expression is never low. This is the case, among others, of
galectin 1 (LEG1), several proteins of the S100-calcium binding
family, and SH3L1, a gene product belonging to the SH3BGR
(SH3 domain-binding glutamic acid-rich-like protein family)
and structurally related to thioredoxin (Trx) super family.29
Psoriasin (S10A7) is one of the most variable proteins among
the 37 patients. It is highly expressed in 15/37 patients, and its
presence may be predictive of invasive and metastaic progres-
sion of the tumor.30–32
The clusters of M/LEP (39.08%) and M/HEP (18.39%) all
together represent the major part of the proteins (57.47%). It
is worth to notice also the presence of “rare” proteins like
TYPH/ PD-ECGF known to be angiogenic growth factors in
vitro and in vivo33 and the cited PARK7.
A general observation concerns the differential expression
of isoelectric variants of the same proteins: very often the level
of intensity of these forms is not the same in different patients,
suggesting the existence of epigenetic factors, differentially
operating in the various tumor environments.
Western Blot Validation of Selected Proteins. Finally, im-
munological assays were performed to confirm the results
obtained by peptide mass fingerprinting in relation to a set of
new proteins, namely, PARK7, S10A7, GDIR, DDAH1, and
DDAH2 (Figure 6). The validation was performed on couples
of patients, chosen among the ones indicated by P01-P37 in
the diagram in Figure 4, respectively, showing high and low
level (or absence) of the cited proteins.
Concluding Remarks
A good performance of proteomic profiling and protein
detection by sequencing methodologies needs remarkable
efforts, both as human and economical resources. Thorough
and courageous selection of results is necessary to ensure high
quality and reliable data. Therefore, to achieve the goal for
Figure 6. Panel showing a Western blot assay to validate a group
of new proteins detected in the breast cancer proteomics by
peptide mass fingerprint. Namely, PARK7, S10A7, GDIR, DDAH1,
and DDAH2. The validation was performed on couples of
patients, chosen among the ones indicated by P01-P37 in the
diagram in Figure 4, respectively, showing high and low level
(or absence) of the cited proteins. On the left: molecular markers.
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translational proteomics, that is, differential diagnosis, prog-
nosis, prediction, and monitor course, collective efforts are to
be encouraged. This study represents a contribution in this
direction.
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